Lupus is a long-term autoimmune disease in which the body's immune system becomes hyperactive and attacks normal, healthy tissue. Scientists have found one side effect of lupus, that it could also make patients more vulnerable to a skin infection, or spreading the infection to others.
The study was published in the Journal of Investigative Dermatology.
Researchers found that 50 per cent of skin rashes in patients with lupus contained an abnormally high presence of a common bacteria responsible for skin infections: Staphylococcus aureus, or more commonly known as staph.
According to J. Michelle Kahlenberg, M.D., Ph.D., associate professor of rheumatology at Michigan Medicine and senior author of the paper, "Fifty per cent of the patients we investigated were colonized by staph, which means the person with the rash is a carrier for the bacteria and can spread it to others."
"In addition, we identified that a protein in the skin of patients with lupus, called interferon, increases the stickiness of staph aureus to their skin."
Kahlenberg had already done previous studies into interferons of the skin of patients with lupus.
"Because our previous work has shown the importance of interferons for sensitivity to sunlight and inflammation in lupus, we then wanted to study whether the interferons and staph were linked," she says.
Kahlenberg notes that while skin rashes are a common side effect of lupus, she and her team were surprised by the abnormally high presence of staph colonisation on the rashes.
"Using a University of Michigan lupus cohort, we found that patients with lupus had staph colonisation on their skin at a rate higher than that reported in healthy adults - 40 per cent compared to 30 per cent," Kahlenberg says. "And when the patients with lupus had active skin rashes or lesions, that rate increased to 50 per cent."
Kahlenberg says the focus on staph bacteria began because it's a leading cause of infection in patients with lupus.
"Others have shown it may be associated with disease flares and development of lupus nephritis, or inflammation of the kidney in patients with lupus," Kahlenberg says.
She is currently enrolling patients in a clinical trial that is testing whether topical antibiotics can decrease inflammation and rashes in the skin of patients with lupus.
"This is important because if true, the addition of topical antibiotics may be a simple way to improve treatment response in lupus skin and reduce the ability for those rashes to be colonized by staph," Kahlenberg says.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
